Trichomonas Vaginalis Recurrence Among HIV+ Women

• Status: Completed
• Trial end date: 2009-08-01
• Target enrollment: 0
• Participant gender: Female

Summary

The purpose of this study is to determine if the 2 gram single dose of metronidazole is as effective as the 7 day 500 mg BID dose for treatment of Trichomonas vaginalis (TV) among HIV-infected women.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Tulane University Health Sciences Center
• Collaborator: National Institute of Allergy and Infectious Diseases (NIAID)
• Treatments: Metronidazole

Criteria

Inclusion Criteria:

• Female

• 18 years or older

• HIV-positive

• TV positive by either wet preparation or culture

• ability to refrain from all alcohol use for 24 hours before and after taking oral metronidazole

• willing to take metronidazole treatment

Exclusion Criteria:

• pregnant

• incarcerated

• previously enrolled

• currently taking disulfiram

• alcoholism or known liver damage

• medical contraindications to metronidazole

• treated with metronidazole within the previous 14 days

• requires treatment for B.V. per Amsel's criteria